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A joint effort among decision-makers, physicians, society, phar-
maceutical industry, and the Mexican scientiﬁc community in
general would be useful for reducing the high costs of these 
diseases.
PIN15
THE EXPECTED ECONOMIC BURDEN OF 
METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS
(MRSA) IN COMPLICATED SKIN AND SKIN STRUCTURE
INFECTIONS (CSSSI)
Mallick R1, Kuznik A1,Weber D2
1Wyeth Research, Collegeville, PA, USA, 2University of North
Carolina, Chapel Hill, NC, USA
OBJECTIVES: To model the expected rate of clinical failure of
initial empiric therapy and economic burden likely to be associ-
ated with the presence of MRSA in patients hospitalized with
cSSSI in the United States. METHODS: Using published data on
1) the prevalence of MRSA and other bacterial pathogens in
cSSSI; 2) the in vitro susceptibility rates of 5 commonly used
antibiotic regimens in cSSSI in relation to the most pervasive
pathogens identiﬁed above; and 3) estimated costs of failure of
initial, empiric treatment of cSSSI from a recent study of a large
US multi-hospital database, we developed a model to simulate
the expected clinical and economic impact of MRSA. RESULTS:
At a base case assumption of a 55% prevalence of Staphylococ-
cus aureus pathogens in cSSSI, half of them being methicillin-
resistant (MRSA = 27.5%), the model projected a clinical failure
rate of 35.9% and weighted mean inpatient treatment costs of
$5492. At an alternative assumption of zero prevalence of
MRSA, the model projected a clinical failure rate of 18.4% and
a weighted mean cost of $4869, yielding $623 ($5492 less
$4869) as the incremental cost of methicillin resistance to the
average patient hospitalized with cSSSI. This translated into an
expected health care burden of approximately $500 million for
the 800,000 patients hospitalized for cSSSI annually. Raising the
market share of antibiotics with in vitro activity against MRSA
from the current 20% to 50% would reduce the expected eco-
nomic burden by $200 million; raising it to 100% would elim-
inate the burden altogether. CONCLUSIONS: Our model
simulated the expected clinical failure rates and economic impact
of use of initial empiric regimens for cSSSI with varying levels of
coverage—as represented by in vitro activity—for MRSA, and
how this expected economic impact may be offset with suitable
change in mix of initial, empiric antibiotic therapy.
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OBJECTIVES: Identify new CDAD cases, readmission rate and
estimate cost over one year. METHODS: All CDAD cases were
identiﬁed in Massachusetts discharge data using ICD-9-CM
codes and patient identiﬁers. Index stays occurred from October
31, 2001–September 30, 2002. The new case cohort excluded
patients with CDAD-related admissions in the previous year. For
primary CDAD cases (principal diagnosis: CDAD), all stay costs
(accommodations and ancillaries) were deemed related. For sec-
ondary CDAD cases, APR-DRG assignment, severity and length
of stay (LOS) were used to calculate the incremental care costs
due to CDAD. All charges were adjusted (cost-to-charge, inﬂa-
tion, geography) to reﬂect national costs (2005 US$). RESULTS:
The 4015 new cases of CDAD identiﬁed reﬂect a prevalence of
1% among hospitalized patients. Almost all (93%) hospitals
treated 1 case (range: 1–312). Of 1310 primary CDAD cases,
66% were female, with mean age of 72 years (±17.2), mean LOS
of 6.9 days (median: 5) and mean cost of $10,260 (median:
$5752) per stay. Secondary CDAD (2705 cases) was similar
demographically but led to longer stays (mean: 15.7, median: 11
days); suffered higher (p < 0.001) inpatient case fatality rates
(13% vs. 5%); and were more expensive than primary cases
(mean: $32,352, median: $16,842). For secondary cases, CDAD-
related costs comprised 40% ($12,999) of total mean cost. Over
one year, 18% of index stay survivors were readmitted for
CDAD, within 51 days on average (mean 1.3 readmissions per
patient, range: 1–6). Total one-year inpatient cost for CDAD
management was estimated at $56 million. CONCLUSIONS:
CDAD has both clinical and economic consequences. It is wide-
spread in hospitals, generates substantial care costs for those
admitted for CDAD management, and increases inpatient costs
dramatically when it occurs as a complication. Recurrent CDAD
leads to re-hospitalization, typically within two months, further
increasing the cost burden of CDAD.
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OBJECTIVES: Although the prevalence of hepatitis C virus
(HCV) infections is higher among the United States veterans than
in the general population, a paucity of pharmacoeconomic
research has been conducted from its perspective. This study
compared the cost-utility of the current peginterferon regimens
from the perspective of the Veterans Affairs (VA) health care
system. METHODS: A Markov model for treatment-naïve
chronic hepatitis C patients was developed to evaluate 1) pegin-
terferon alfa-2a plus ribavirin (PEG 2a + R); 2) peginterferon
alfa-2b plus ribavirin (PEG 2b + R); and 3) no therapy. Patient
cohorts were 45 or 55 year-old males with liver ﬁbrosis and
without cirrhosis. Data for the model were obtained from clini-
cal trials and published literature. All costs were based on VA
costs and reﬂect 2005 U.S. dollars. The lifetime expected costs,
quality-adjusted life years (QALYs) gained, and incremental net
monetary beneﬁt (INMB) with HCV treatments were deter-
mined. Ninety-ﬁve percent conﬁdence intervals (CI) were gener-
ated from the Monte Carlo simulations. RESULTS: Both
peginterferon regimens were signiﬁcantly more cost-effective
than no treatment, though no differences in costs or QALYs were
noted between the two peginterferon regimens. For 45 year-old
cohort with a genotype 1 infection, the INMB was $128,583
(95% CI $79,279 to $177,308) and $128,025 (95% CI $80,425
to $173,448) versus no treatment for PEG 2a + R and PEG 2b
+ R, respectively. Treatment with either peginterferon regimen
produced signiﬁcantly lower lifetime HCV-related medical costs
for genotype 2 or 3 infections, but not genotype 1. CONCLU-
SIONS: PEG 2a + R and PEG 2b + R were found to be similar
cost-effective treatments for patients with HCV infections, par-
ticularly with genotypes 2 and 3. However, no signiﬁcant differ-
ences in costs or efﬁcacy were observed between these treatment
regimens.
